HealthTech Aplagon, a Helsinki-based medical stage biopharmaceutical firm creating a first-in-class therapeutic APAC for thrombo-inflammatory illnesses, introduced at this time it has closed a €7 million financing.
The funding spherical was led by new buyers Fåhraeus Startup and Progress AB (FSG), a Nordic enterprise capital fund, and European Innovation Council (EIC) Fund. FSG and EIC Fund have been joined by main Finnish buyers, together with Jenny and Antti Wihuri Basis, Innovestor and Gösta Serlachius High-quality Arts Basis.
Johanna Asklin will even be a part of Aplagon as a Board member and Alexander Jöndell, Associate at FSG, as an Observer.
Aki Prihti, CEO at Aplagon, stated, “We’re delighted to safe this fund-raising, and to carry on board FSG and EIC Fund as extremely skilled VC buyers from exterior Finland. Now we have been making robust progress, and this financing allows us to finish the three worldwide medical trials we now have been operating with APAC, and to start out a Part 2a examine in PAOD/CLTI. Our progressive strategy, utilizing a heparin proteoglycan mimetic with concentrating on means and retention on the vascular damage websites, has potential functions throughout a broad vary of great vascular illnesses. We’re trying ahead to saying medical outcomes from these trials in 2025 and 2026.”
Aplagon is a medical stage biopharmaceutical firm creating a first-in-class therapeutic APAC for treating thrombo-inflammatory illnesses. The corporate’s first two lead indications are:
- The prevention of AVF maturation failure, to allow lifesaving haemodialysis remedy in end-stage kidney illness sufferers,
- CLTI, to stop amputations and different main cardiovascular occasions in CLTI sufferers.
Based in 2009, Aplagon and its therapeutic APAC are based mostly on the analysis on mast cell-derived heparin proteoglycans carried out by Prof. Riitta Lassila and associates at Wihuri Analysis Institute in Helsinki, Finland. Aplagon is backed by a syndicate of main Nordic buyers together with FSG Fund, Wihuri Basis, Innovestor and Serlachius Basis in addition to EIC Fund.
By mimicking naturally occurring mast cell-derived heparin proteoglycans, APAC targets arterial damage websites offering long-lasting antithrombotic and anti inflammatory motion in situ.
The funding will help the initiation of Part 2a medical trial of APAC for peripheral arterial occlusive illness/persistent limb threatening ischemia (PAOD/CLTI) in Finland. APAC can be poised to finish three ongoing medical trials; a Part I medical trial for Arteriovenous Fistula (AVF) maturation failure, a Part I intravenous (IV) medical trial in wholesome members, and a PET-imaging medical trial with zirconium-labeled APAC in PAOD sufferers and wholesome members in 2025.
APAC is meant for in-hospital use and might be administered both domestically or by IV infusion. Over 40 members have to date acquired APAC with none security issues and preliminary medical findings are encouraging – in accordance with Aplagon.
Johanna Asklin, Basic Associate at FSG, stated, “Thrombo-inflammation is a key underlying driver for a lot of cardiovascular illnesses. At FSG we search for revolutionary improvements, and we discovered exactly that with Aplagon’s APAC strategy to deal with this clear unmet medical want.”
